ENCALERET SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C29H33ClFNO4.H2O.H2O4S
Molecular Weight	1144.15
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.OS(O)(=O)=O.C[C@@H](OC[C@H](O)CNC(C)(C)CC1=CC(F)=C(Cl)C=C1)C2=C(C=CC=C2)C3=CC=C(C(O)=O)C(C)=C3.C[C@@H](OC[C@H](O)CNC(C)(C)CC4=CC(F)=C(Cl)C=C4)C5=C(C=CC=C5)C6=CC=C(C(O)=O)C(C)=C6

InChI

InChIKey=NOJBHZIZNPMQRT-CBASKZFISA-N

InChI=1S/2C29H33ClFNO4.H2O4S.H2O/c2*1-18-13-21(10-11-23(18)28(34)35)25-8-6-5-7-24(25)19(2)36-17-22(33)16-32-29(3,4)15-20-9-12-26(30)27(31)14-20;1-5(2,3)4;/h2*5-14,19,22,32-33H,15-17H2,1-4H3,(H,34,35);(H2,1,2,3,4);1H2/t2*19-,22-;;/m11../s1

HIDE SMILES / InChI

Molecular Formula	C29H33ClFNO4
Molecular Weight	514.028
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800023553 | https://www.ncbi.nlm.nih.gov/pubmed/21810422 | https://www.ncbi.nlm.nih.gov/pubmed/25166719 | https://www.ncbi.nlm.nih.gov/pubmed/26556736

Encaleret (JTT-305 or MK-5442) is a potent oral short-acting calcium-sensing receptor (CaSR) antagonist and transiently stimulates endogenous parathyroid hormone (PTH) secretion. CaSR antagonists stimulate endogenous PTH secretion through CaSR on the surface of parathyroid cells and thereby may be anabolic agents for osteoporosis. Japan Tobacco and Merck were developing encaleret for the treatment of osteoporosis however development has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
[Antagonist for calcium-sensing receptor. JTT-305/MK-5442].	2011 Jan	21187599
Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats.	2012 Jun	22445539
A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans.	2013 Aug	23436611

Patents

Sample Use Guides

In Vivo Use Guide

Phase II studies: 2.5 - 15 mg daily

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:20:14 GMT 2023` Edited by `admin` on `Fri Dec 15 18:20:14 GMT 2023`
Record UNII	7CKZ1Y8K70
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENCALERET SULFATE

Official Name

English

JIT-305

Common Name

English

BIS((2R)-3-((1R)-1-(4'-CARBOXY-3'-METHYL(1,1'-BIPHENYL)-2-YL)ETHOXY)-N-(1-(4-CHLORO-3-FLUOROPHENYL)-2-METHYLPROPAN-2-YL)-2-HYDROXYPROPAN-1-AMINIUM) SULFATE HYDRATE

Common Name

English

MK5442

Code

English

Encaleret sulfate [WHO-DD]

Common Name

English

BIS(2'-((1R)-1-((2R)-3-((2-(4-CHLORO-3-FLUOROPHENYL)-1,1-DIMETHYLETHYL)AMINO)-2-HYDROXYPROPOXY)ETHYL)-3-METHYLBIPHENYL-4-CARBOXYLIC ACID) SULFATE MONOHYDRATE

Common Name

English

MK-5442

Code

English

(1,1'-BIPHENYL)-4-CARBOXYLIC ACID, 2'-((1R)-1-((2R)-3-((2-(4-CHLORO-3-FLUOROPHENYL)-1,1-DIMETHYLETHYL)AMINO)-2-HYDROXYPROPOXY)ETHYL)-3-METHYL-, SULFATE, HYDRATE (2:1:1)

Common Name

English

ENCALERET SULFATE [USAN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

782120